SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2019 / Cilt: 49 - Sayı: 3

The relationship between serum levels of surfactant protein D in COPD exacerbation severity and mortality

Fatma Esra GÜNAYDIN
Sedat ALTIN
Barış DEMİRKOL
Gülşah GÜNLÜOĞLU
Esma Nur AKTEPE
Nurdan KALKAN
Pages
888–893
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a correlation between the rate of emergency admission andserum SP-D levels during the 12-month period after discharge (P = 0.04 (r = 0.29)).Conclusion: Our study showed that serum SP-D was found to be a useful biomarker in predicting emergency admission and predictorof the health status of COPD patients but did not predict early mortality after the exacerbation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality.
📊
Key Findings & Data:In COPD patients,various inflammatory markers such as cytokines and acute phase proteins, which show systemic inflammation in the circulation,increase during exacerbations.
💡
Conclusion & Impact:There was a correlation between the rate of emergency admission andserum SP-D levels during the 12-month period after discharge (P = 0.04 (r = 0.29)).Conclusion: Our study showed that serum SP-D was found to be a useful biomarker in predicting emergency admission and predictorof the health status of COPD patients but did not predict early mortality after the exacerbation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality. In COPD patients,various inflammatory markers such as cytokines and acute phase proteins, which show systemic inflammation in the circulation,increase during exacerbations. In our study, we aimed to determine the relationship between serum SP-D levels and exacerbationseverity, clinical course of the disease, and early mortality after discharge.Materials and methods: Fifty hospitalized patients with COPD acute exacerbation (46 male and 4 female) were recruited in this study.Thirty-three of the subjects (31 male and 2 female) were reevaluated after discharge. Venous blood samples were taken from all patientsand followed up for exacerbation frequency, hospital admission, and mortality for 12 months.Results: Serum SP-D levels in the stable period of the patients were lower than exacerbation (P < 0.001). The median exacerbationperiod SP-D level of the patients admitted to emergency department in the first month was statistically significantly higher than thatof the patients who were not admitted (P < 0.05) after discharge. There was a correlation between the rate of emergency admission andserum SP-D levels during the 12-month period after discharge (P = 0.04 (r = 0.29)).Conclusion: Our study showed that serum SP-D was found to be a useful biomarker in predicting emergency admission and predictorof the health status of COPD patients but did not predict early mortality after the exacerbation.

🔖

Cite This Article

GÜNAYDIN, F. E., ALTIN, S., DEMİRKOL, B., GÜNLÜOĞLU, G., AKTEPE, E. N., KALKAN, N. (2022). The relationship between serum levels of surfactant protein D in COPD exacerbation severity and mortality. Turkish Journal of Medical Sciences, Cilt: 49 - Sayı: 3, 888–893. https://ajindex.com/articles/609975

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Fontana, USA: Global Initiative for Chronic Obstructive Lung Disease, Inc; 2018
  2. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R, Ivanov Y, Kostov K, Bourbeau J et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009; 34: 95-102. doi: 10.1183/09031936.00156508 3. Sin DD, Hollander Z, DeMarco ML, McManus BM, Ng RT. Biomarker development for chronic obstructive pulmonary disease from discovery to clinical implementation. Am J Respir Crit Care Med 2015; 192: 1162-1170. doi: 10.1164/ rccm.201505-0871PP
  3. Moreno D, Garcia A, Lema D, De Sanctis JB. Surfactant protein D in chronic obstructive pulmonary disease (COPD). Recent Pat Endocr Metab Immune Drug Discov 2014; 8: 42-47
  4. Hartshorn K, Chang D, Rust K, Crouch EC. Interactions of recombinant human pulmonary Surfactant Protein D and SP-D multimers with influenza A. Am J Physiol 1996; 271: 753- 762
  5. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995, 152: 1860-1866
  6. Sin DD, Leung R, Gan WQ, Man SP. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007; 7: 13- 20. doi: 10.1186/1471-2466-7-13 8. Ju CR, Liu W and Chen RC. Serum surfactant protein D: Biomarker of chronic obstructive pulmonary disease. Dis Markers 2012; 32: 281-287. doi: 10.3233/DMA-2011-0887
  7. Shakoori TA, Sin DD, Ghafoor F, Bashir S and Bokhari SN. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease. Dis Markers 2014; 27: 287-294. doi: 10.3233/DMA-2009-0674
  8. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-38. doi: 10.1056/NEJMoa0909883
  9. Alaabder A, Mohammad Y, Fahoum S. The role of serum SP-D in COPD. Qatar Med J 2015; 2015: 18. doi: 10.5339/ qmj.2015.18
  10. Lomas DA, Silverman EK, Edwards LD, Locantore NW, Miller BE, Horstman DH, Tal-Singer R. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;